Abstract
Genetic variations in CYP3A4, CYP3A5, and m-TOR could contribute to interpatient variability regarding m-TOR inhibitors pharmacokinetics or cellular effects. The purpose of this study was to evaluate the influence of selected candidate variations in these genes on everolimus pharmacokinetics, efficacy, and toxicity in cancer patients. Thirty-four patients receiving everolimus for breast (n = 22) or renal (n = 10) cancers, or neuroendocrine tumors of pancreatic origin (n = 2) were included in the study. Six variants in genes related to everolimus pharmacokinetics (CYP3A4*22 and CYP3A5*3) or pharmacodynamics (m-TOR rs2295079, rs2295080, rs2024627 and rs1057079) were genotyped. Associations with trough concentrations (C0), dose reductions, or treatment interruptions due to toxicity and progression-free survival were investigated using generalized estimating equations and Cox models. CYP3A5 nonexpressers had significantly higher C0 as compared with expressers (βGG vs AG = + 6.32 ± 2.22 ng/mL, p = 0.004). m-TOR rs2024627 was significantly associated with an increased risk of cancer progression studied alone or as part of an haplotype (T vs C: HR = 2.60, 95% CI [1.16–5.80], p = 0.020; CTCG vs other haplotypes HR = 2.29, 95% CI [1.06–4.95], p = 0.035, respectively). This study showed that CYP3A5 expression impacts everolimus pharmacokinetics in cancer patients and identified a genetic variation in m-TOR associated with the risk of cancer progression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Code availability
R code used in the present article is available under request.
References
Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol J Am Soc Clin Oncol. 2009;27:2278–87.
Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer. N Engl J Med. 2012;366:520–9.
Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514–23.
Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet Lond Engl. 2011;378:2005–12.
Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet Lond Engl. 2008;372:449–56.
Picard N, Rouguieg-Malki K, Kamar N, Rostaing L, Marquet P. CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients. Transplantation. 2011;91:652–6.
Wang D, Guo Y, Wrighton S, Cooke G, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 2011;11:274–86.
Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27:383–91.
Moes DJAR Swen JJ, den Hartigh J, van der Straaten T, van der Heide JJH, Sanders JS, et al. Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on cyclosporine, everolimus, and tacrolimus pharmacokinetics in renal transplantation. CPT Pharmacometrics Syst Pharm. 2014;3:e100.
Shipkova M, Hesselink DA, Holt DW, Billaud EM, van Gelder T, Kunicki PK, et al. Therapeutic drug monitoring of everolimus: a consensus report. Ther Drug Monit. 2016;38:143–69.
Woillard J-B, Chouchana L, Picard N, Loriot M-A. French network of pharmacogenetics (RNPGX). Pharmacogenetics of immunosuppressants: state of the art and clinical implementation—recommendations from the French National Network of Pharmacogenetics (RNPGx). Therapie. 2017;72:285–99.
Moes DJAR, Press RR, den Hartigh J, van der Straaten T, de Fijter JW, Guchelaar H-J. Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. Clin Pharmacokinet. 2012;51:467–80.
Kniepeiss D, Renner W, Trummer O, Wagner D, Wasler A, Khoschsorur GA, et al. The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation. Clin Transpl. 2011;25:146–50.
Schoeppler KE, Aquilante CL, Kiser TH, Fish DN, Zamora MR. The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients. Clin Transpl. 2014;28:590–7.
Lesche D, Sigurdardottir V, Setoud R, Englberger L, Fiedler GM, Largiadèr CR, et al. Influence of CYP3A5 genetic variation on everolimus maintenance dosing after cardiac transplantation. Clin Transpl. 2015;29:1213–20.
Pascual T, Apellániz-Ruiz M, Pernaut C, Cueto-Felgueroso C, Villalba P, Álvarez C, et al. Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer. PLoS ONE. 2017;12. https://doi.org/10.1371/journal.pone.0180192.
Elens L, Haufroid V. Genotype-based tacrolimus dosing guidelines: with or without CYP3A4*22? Pharmacogenomics. 2017;18:1473–80.
Woillard J-B, Kamar N, Rousseau A, Rostaing L, Marquet P, Picard N. Association of sirolimus adverse effects with m-TOR, p70S6K or Raptor polymorphisms in kidney transplant recipients. Pharmacogenet Genomics. 2012;22:725–32.
Pouché L, Stojanova J, Marquet P, Picard N. New challenges and promises in solid organ transplantation pharmacogenetics: the genetic variability of proteins involved in the pharmacodynamics of immunosuppressive drugs. Pharmacogenomics. 2016;17:277–96.
Deppenweiler M, Falkowski S, Saint-Marcoux F, Monchaud C, Picard N, Laroche M-L, et al. Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure-effect relationship. Pharm Res. 2017;121:138–44.
Slattery ML, Lundgreen A, Mullany LE, Penney RB, Wolff RK. Influence of CHIEF pathway genes on gene expression: a pathway approach to functionality. Int J Mol Epidemiol Genet. 2014;5:100–11.
Cao Q, Ju X, Li P, Meng X, Shao P, Cai H, et al. A functional variant in the MTOR promoter modulates its expression and is associated with renal cell cancer risk. PLoS ONE. 2012;7. https://doi.org/10.1371/journal.pone.0050302.
Zhao Y, Diao Y, Wang X, Lin S, Wang M, Kang H, et al. Impacts of the mTOR gene polymorphisms rs2536 and rs2295080 on breast cancer risk in the Chinese population. Oncotarget. 2016;7:58174–80.
Speidel JT, Xu M, Abdel-Rahman SZ. Differential effect of ABCB1 haplotypes on promoter activity. Pharmacogenet Genomics. 2018;28:69–77.
Acknowledgements
We are grateful to K. Poole for manuscript editing.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
SF receives funding from Novartis, Pfizer, Sanofi, BMS, Jansen, and Amgen; the other authors have no conflict of interest to declare.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Bonnet, S., Falkowski, S., Deppenweiler, M. et al. Effect of genetic polymorphisms in CYP3A4, CYP3A5, and m-TOR on everolimus blood exposure and clinical outcomes in cancer patients. Pharmacogenomics J 20, 647–654 (2020). https://doi.org/10.1038/s41397-020-0152-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41397-020-0152-7